Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Oncology
Link
https://link.springer.com/content/pdf/10.1007/s11864-020-00768-2.pdf
Reference94 articles.
1. Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Ann Global Health. 2019;85(1)8. https://doi.org/10.5334/aogh.2419.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
3. Wistuba II, Brambilla E, Noguchi M. Classic Anatomic Pathology and Lung Cancer. In: Pass HI, Ball D, Scagliotti GV, editors. IASLC Thoracic Oncology (Second Edition). Philadelphia; 2018. p. 143-63.e4.
4. • Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, Chang JY, et al. NCCN guidelines insights: non-small cell lung cancer, Version 5.2018. J Natl Compr Cancer Netw. 2018;16(7):807–21 Evidence based guidelines insights on management of NSCLC with focus on immunotherpy and targetted therapy.
5. • Hanna N, Johnson D, Temin S, Baker S Jr, Brahmer J, Ellis PM, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017;35(30):3484–515 Evidence based guidelines and recommendations on management of stage IV NSCLC.
Cited by 27 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. An ultra-long-acting L-asparaginase synergizes with an immune checkpoint inhibitor in starvation-immunotherapy of metastatic solid tumors;Biomaterials;2025-01
2. Influence of Financial Toxicity on the Quality of Life in Lung Cancer Patients Undergoing Immunotherapy: The Mediating Effect of Self-Perceived Burden;Cancer Management and Research;2024-08
3. Good response of cadonilimab (PD-1/CTLA-4 bi-specific antibody) to patients with advanced lung adenocarcinoma after immunotherapy resistance: A case report;Asian Journal of Surgery;2024-07
4. The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors;Japanese Journal of Clinical Oncology;2024-05-20
5. Immunotherapy-associated symptoms, distress, financial toxicity and unmet supportive care needs of patients with cancer;European Journal of Oncology Nursing;2024-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3